277 related articles for article (PubMed ID: 22728225)
1. Advax™, a polysaccharide adjuvant derived from delta inulin, provides improved influenza vaccine protection through broad-based enhancement of adaptive immune responses.
Honda-Okubo Y; Saade F; Petrovsky N
Vaccine; 2012 Aug; 30(36):5373-81. PubMed ID: 22728225
[TBL] [Abstract][Full Text] [Related]
2. Advax delta inulin adjuvant overcomes immune immaturity in neonatal mice thereby allowing single-dose influenza vaccine protection.
Honda-Okubo Y; Ong CH; Petrovsky N
Vaccine; 2015 Sep; 33(38):4892-900. PubMed ID: 26232344
[TBL] [Abstract][Full Text] [Related]
3. A single immunization with inactivated H1N1 influenza vaccine formulated with delta inulin adjuvant (Advax™) overcomes pregnancy-associated immune suppression and enhances passive neonatal protection.
Honda-Okubo Y; Kolpe A; Li L; Petrovsky N
Vaccine; 2014 Aug; 32(36):4651-9. PubMed ID: 24958701
[TBL] [Abstract][Full Text] [Related]
4. A novel hepatitis B vaccine containing Advax™, a polysaccharide adjuvant derived from delta inulin, induces robust humoral and cellular immunity with minimal reactogenicity in preclinical testing.
Saade F; Honda-Okubo Y; Trec S; Petrovsky N
Vaccine; 2013 Apr; 31(15):1999-2007. PubMed ID: 23306367
[TBL] [Abstract][Full Text] [Related]
5. A gold glyco-nanoparticle carrying a Listeriolysin O peptide and formulated with Advax™ delta inulin adjuvant induces robust T-cell protection against listeria infection.
Rodriguez-Del Rio E; Marradi M; Calderon-Gonzalez R; Frande-Cabanes E; Penadés S; Petrovsky N; Alvarez-Dominguez C
Vaccine; 2015 Mar; 33(12):1465-73. PubMed ID: 25659269
[TBL] [Abstract][Full Text] [Related]
6. Delta inulin polysaccharide adjuvant enhances the ability of split-virion H5N1 vaccine to protect against lethal challenge in ferrets.
Layton RC; Petrovsky N; Gigliotti AP; Pollock Z; Knight J; Donart N; Pyles J; Harrod KS; Gao P; Koster F
Vaccine; 2011 Aug; 29(37):6242-51. PubMed ID: 21736913
[TBL] [Abstract][Full Text] [Related]
7. Advax augments B and T cell responses upon influenza vaccination via the respiratory tract and enables complete protection of mice against lethal influenza virus challenge.
Tomar J; Patil HP; Bracho G; Tonnis WF; Frijlink HW; Petrovsky N; Vanbever R; Huckriede A; Hinrichs WLJ
J Control Release; 2018 Oct; 288():199-211. PubMed ID: 30218687
[TBL] [Abstract][Full Text] [Related]
8. An alphavirus-based adjuvant enhances serum and mucosal antibodies, T cells, and protective immunity to influenza virus in neonatal mice.
Khalil SM; Tonkin DR; Snead AT; Parks GD; Johnston RE; White LJ
J Virol; 2014 Aug; 88(16):9182-96. PubMed ID: 24899195
[TBL] [Abstract][Full Text] [Related]
9. Human Phase 1 trial of low-dose inactivated seasonal influenza vaccine formulated with Advax™ delta inulin adjuvant.
Gordon DL; Sajkov D; Honda-Okubo Y; Wilks SH; Aban M; Barr IG; Petrovsky N
Vaccine; 2016 Jul; 34(33):3780-6. PubMed ID: 27342914
[TBL] [Abstract][Full Text] [Related]
10. Advax™, a novel microcrystalline polysaccharide particle engineered from delta inulin, provides robust adjuvant potency together with tolerability and safety.
Petrovsky N; Cooper PD
Vaccine; 2015 Nov; 33(44):5920-6. PubMed ID: 26407920
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant use of the NKT cell agonist alpha-galactosylceramide leads to enhancement of M2-based DNA vaccine immunogenicity and protective immunity against influenza A virus.
Fotouhi F; Shaffifar M; Farahmand B; Shirian S; Saeidi M; Tabarraei A; Gorji A; Ghaemi A
Arch Virol; 2017 May; 162(5):1251-1260. PubMed ID: 28120096
[TBL] [Abstract][Full Text] [Related]
12. Randomized clinical trial of immunogenicity and safety of a recombinant H1N1/2009 pandemic influenza vaccine containing Advax™ polysaccharide adjuvant.
Gordon DL; Sajkov D; Woodman RJ; Honda-Okubo Y; Cox MM; Heinzel S; Petrovsky N
Vaccine; 2012 Aug; 30(36):5407-16. PubMed ID: 22717330
[TBL] [Abstract][Full Text] [Related]
13. An Advax-CpG adjuvanted recombinant H5 hemagglutinin vaccine protects mice against lethal influenza infection.
Honda-Okubo Y; Bart Tarbet E; Hurst BL; Petrovsky N
Vaccine; 2023 Sep; 41(39):5730-5741. PubMed ID: 37567799
[TBL] [Abstract][Full Text] [Related]
14. Inactivated Influenza Vaccine That Provides Rapid, Innate-Immune-System-Mediated Protection and Subsequent Long-Term Adaptive Immunity.
Chua BY; Wong CY; Mifsud EJ; Edenborough KM; Sekiya T; Tan AC; Mercuri F; Rockman S; Chen W; Turner SJ; Doherty PC; Kelso A; Brown LE; Jackson DC
mBio; 2015 Oct; 6(6):e01024-15. PubMed ID: 26507227
[TBL] [Abstract][Full Text] [Related]
15. Synthetic Toll-Like Receptor 4 (TLR4) and TLR7 Ligands Work Additively via MyD88 To Induce Protective Antiviral Immunity in Mice.
Goff PH; Hayashi T; He W; Yao S; Cottam HB; Tan GS; Crain B; Krammer F; Messer K; Pu M; Carson DA; Palese P; Corr M
J Virol; 2017 Oct; 91(19):. PubMed ID: 28724768
[TBL] [Abstract][Full Text] [Related]
16. Enhanced Influenza Virus-Like Particle Vaccination with a Structurally Optimized RIG-I Agonist as Adjuvant.
Beljanski V; Chiang C; Kirchenbaum GA; Olagnier D; Bloom CE; Wong T; Haddad EK; Trautmann L; Ross TM; Hiscott J
J Virol; 2015 Oct; 89(20):10612-24. PubMed ID: 26269188
[TBL] [Abstract][Full Text] [Related]
17. Recombinant H5 hemagglutinin adjuvanted with nanoemulsion protects ferrets against pathogenic avian influenza virus challenge.
Wang SH; Smith D; Cao Z; Chen J; Acosta H; Chichester JA; Yusibov V; Streatfield SJ; Fattom A; Baker JR
Vaccine; 2019 Mar; 37(12):1591-1600. PubMed ID: 30795941
[TBL] [Abstract][Full Text] [Related]
18. Immunogenicity and safety of Advax™, a novel polysaccharide adjuvant based on delta inulin, when formulated with hepatitis B surface antigen: a randomized controlled Phase 1 study.
Gordon D; Kelley P; Heinzel S; Cooper P; Petrovsky N
Vaccine; 2014 Nov; 32(48):6469-77. PubMed ID: 25267153
[TBL] [Abstract][Full Text] [Related]
19. Safety and immunogenicity of a delta inulin-adjuvanted inactivated Japanese encephalitis virus vaccine in pregnant mares and foals.
Bielefeldt-Ohmann H; Prow NA; Wang W; Tan CS; Coyle M; Douma A; Hobson-Peters J; Kidd L; Hall RA; Petrovsky N
Vet Res; 2014 Dec; 45(1):130. PubMed ID: 25516480
[TBL] [Abstract][Full Text] [Related]
20. Cationic lipid/DNA complexes (JVRS-100) combined with influenza vaccine (Fluzone) increases antibody response, cellular immunity, and antigenically drifted protection.
Lay M; Callejo B; Chang S; Hong DK; Lewis DB; Carroll TD; Matzinger S; Fritts L; Miller CJ; Warner JF; Liang L; Fairman J
Vaccine; 2009 Jun; 27(29):3811-20. PubMed ID: 19406188
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
